文献速递哮喘

高剂量吸入糖皮质激素在哮喘中的口服激素节约效应

Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma.
PubMed 文献 · Eur Respir J · 2020-01-02

本研究通过系统综述与荟萃分析评估口服激素依赖性哮喘中高剂量ICS的口服激素节约效应,共纳入11项RCT含1283例受试者。每增加1000μg ICS,泼尼松减量因ICS类型而异为2.1-4.9mg;因全身效应所致的泼尼松节约效应比值,丙酸氟替卡松为1.02(95%CI 0.68-2.08),布地奈德为0.93(95%CI 0.63-1.89)。结论提示该节约效应大部分可能源于全身效应。

要点

  • 口服激素依赖性哮喘中,高剂量ICS每增1000μg可减少泼尼松2.1-4.9mg,因ICS类型而异。
  • 因全身效应所致的泼尼松节约比值:丙酸氟替卡松1.02(95%CI 0.68-2.08),布地奈德0.93(95%CI 0.63-1.89)。
  • 有限证据提示高剂量ICS的口服激素节约效应大部分可能归因于全身效应。

核心结论

  • 在口服激素依赖性哮喘患者中,有限证据提示高剂量ICS的口服激素节约效应大部分可能源于其全身效应。

研究设计与样本

  • 系统综述与荟萃分析,纳入报告高剂量ICS口服激素节约效应的随机对照试验。
  • 共纳入11项研究、1283例受试者。
  • 同时检索口服激素与ICS在肾上腺抑制方面的剂量等效性报告。

主要发现

  • 每增加1000μg ICS,泼尼松剂量减少范围因ICS类型不同为2.1mg至4.9mg。
  • 因全身效应所致的每1000μg丙酸氟替卡松泼尼松节约效应比值为1.02(95%CI 0.68-2.08)。
  • 因全身效应所致的每1000μg布地奈德泼尼松节约效应比值为0.93(95%CI 0.63-1.89)。

临床怎么用

  • 对口服激素依赖性哮喘患者使用高剂量ICS时,应认识到其口服激素节约效应可能主要来自全身吸收而非局部作用。

局限性

  • 证据有限,仅基于11项报告口服激素节约效应的随机对照试验。
  • 口服激素节约效应比值是基于肾上腺抑制的等效性间接估算。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The proportion of the efficacy of high-dose inhaled corticosteroids (ICS) in oral corticosteroid-dependent asthma that is due to systemic effects is uncertain. This study aimed to estimate the ICS dose-response relationship for oral corticosteroid-sparing effects in oral corticosteroid-dependent asthma, and to determine the proportion of oral corticosteroid-sparing effects due to their systemic effects, based on the comparative dose-response relationship of ICS versus oral corticosteroids on adrenal suppression. METHODS: Systematic review and meta-analysis of randomised controlled trials reporting oral corticosteroid-sparing effects of high-dose ICS in oral corticosteroid-dependent asthma. In addition, reports of oral corticosteroid to ICS dose-equivalence in terms of adrenal suppression were retrieved. The primary outcome was the proportion of the oral corticosteroid-sparing effect of ICS that could be attributed to systemic absorption, per 1000 µg increase of ICS, expressed as a ratio. This ratio estimates the oral corticosteroid sparing effect of ICS due to systemic effects. RESULTS: 11 studies including 1283 participants reporting oral corticosteroid-sparing effects of ICS were identified. The prednisone dose decrease per 1000 µg increase in ICS varied from 2.1 mg to 4.9 mg, depending on the type of ICS. The ratio of the prednisone-sparing effect due to the systemic effects per 1000 µg of fluticasone propionate was 1.02 (95% CI 0.68-2.08) and for budesonide was 0.93 (95% CI 0.63-1.89). CONCLUSION: In patients with oral corticosteroid-dependent asthma, the limited available evidence suggests that the majority of the oral corticosteroid-sparing effect of high-dose ICS is likely to be due to systemic effects.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Maijers I, Kearns N, Harper J, et al. Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma. Eur Respir J. 2020. PMID: 31558659. doi:10.1183/13993003.01147-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。